Affinity Asset Advisors’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$46.2M Sell
700,483
-99,517
-12% -$6.32M 2.71% 12
2025
Q4
$50.8M Buy
800,000
+450,000
+129% +$28M 3.65% 9
2025
Q3
$19.2M Buy
+350,000
New +$14.4M 1.79% 20
2024
Q2
Sell
-80,000
Closed -$5.61M 112
2024
Q1
$5.61M Sell
80,000
-80,000
-50% -$6.19M 0.91% 44
2023
Q4
$13.4M Sell
160,000
-70,366
-31% -$2.55M 2.66% 15
2023
Q3
$6.79M Buy
230,366
+105,218
+84% +$3.5M 2.22% 17
2023
Q2
$4.08M Sell
125,148
-96,315
-43% -$3.56M 1.61% 24
2023
Q1
$7.79M Buy
221,463
+133,862
+153% +$5.46M 2.99% 11
2022
Q4
$4.01M Buy
87,601
+22,601
+35% +$972K 1.84% 23
2022
Q3
$3.15M Buy
65,000
+50,000
+333% +$2.41M 1.45% 34
2022
Q2
$589K Buy
+15,000
New +$604K 0.32% 45
2022
Q1
Sell
-145,552
Closed -$6.63M 71
2021
Q4
$6.63M Buy
145,552
+20,552
+16% +$793K 2.83% 17
2021
Q3
$4.47M Buy
125,000
+55,000
+79% +$1.62M 1.78% 23
2021
Q2
$1.39M Buy
70,000
+30,000
+75% +$704K 0.66% 46
2021
Q1
$930K Sell
40,000
-30,000
-43% -$641K 0.46% 49
2020
Q4
$1.46M Buy
+70,000
New +$1.28M 0.9% 34

Other funds holding CYTK